Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients

2016 ◽  
Vol 77 (5) ◽  
pp. 586-592 ◽  
Author(s):  
Alireza Esteghamati ◽  
Alireza Momeni ◽  
Ali Abdollahi ◽  
Amirhossein Khandan ◽  
Mohsen Afarideh ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Type 2 Diabetic ◽  
Type 2 Diabetic Retinopathy

scholarly journals Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes

2021 ◽  
Vol 9 (1) ◽  
pp. e002126
Author(s):  
Shi Jin ◽  
Ning Xia ◽  
Lingling Han
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Increased Risk ◽  
Significant Difference ◽  
Fgf21 Level

IntroductionWe conducted this cross-sectional study to explore the relationship between serum fibroblast growth factor 21 (FGF21) level and sight-threatening diabetic retinopathy (STDR).Research design and methodsA total of 654 patients with type 2 diabetes were recruited. Diabetic retinopathy (DR) was evaluated by the bilateral retinal photography, and patients were assigned into groups of no DR (NDR) (n=345, 52.75%), non-sight-threatening diabetic retinopathy (NSTDR) (n=207, 31.65%), involving patients with mild or moderate non-proliferative retinopathy (NPDR) and STDR (n=102, 15.60%), including those with severe NPDR or proliferative diabetic retinopathy (PDR). Serum FGF21 levels were quantified by a sandwich ELISA. Patients were divided into quartiles according to their serum FGF21 level.ResultsThere was a significant difference in serum FGF21 level among the three groups of patients (p<0.01). Compared with other quartiles (Q1–Q3), the patients in Q4 had a higher prevalence of DR and STDR (p<0.05). Compared with Q1, a positive association was observed between serum FGF21 level and DR in Q3 and Q4 (p<0.01). After adjusting for age, gender and other risk factors, serum FGF21 level in Q4 was found to be associated with increased risk of DR and STDR (p<0.01). Serum FGF21 level was noted as an independent risk factor for DR and STDR (p<0.01). Serum FGF21 level >478.76 pg/mL suggested the occurrence of DR and that level >554.69 pg/mL indicated STDR (p<0.01).ConclusionsSerum FGF21 level was a biomarker for the risk of developing DR or STDR. The risk of STDR increased when the serum FGF21 level of patients with type 2 diabetes was >554.69 pg/mL.

Fibroblast growth factor 21 as a predictor of early stage diabetic nephropathy in type 2 diabetic mellitus

2019 ◽  
Vol 22 (07) ◽  
pp. 01-07
Author(s):  
Samah Naji ◽  
Kareem Ghali ◽  
Najah Hadi ◽  
Maysaa Ali Abdul khaleq ◽  
Mohammed Abdelhussain
Keyword(s):  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Early Stage ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Diabetic Mellitus ◽  
Type 2 Diabetic Mellitus ◽  
Type 2 Diabetic

scholarly journals Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice

Endocrinology ◽  
2013 ◽  
Vol 154 (9) ◽  
pp. 3366-3376 ◽  
Author(s):  
H. W. Kim ◽  
J. E. Lee ◽  
J. J. Cha ◽  
Y. Y. Hyun ◽  
J. E. Kim ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Renal Injury ◽  
Mesangial Cells ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Type 2 Diabetic

Despite the emerging importance of fibroblast growth factor 21 (FGF21) as a metabolic hormone regulating energy balance, its direct effects on renal function remain unexplored. FGF21 was injected ip daily for 12 weeks into db/db mice. Compared with control vehicle injection, FGF21 treatment significantly improved lipid profiles and insulin resistance and resulted in significantly higher serum adiponectin levels. In contrast, serum insulin and 8-isoprostane levels were significantly decreased. Interestingly, FGF21 and its receptor components in the kidneys were found to be significantly up-regulated in db/db mice, which suggests an FGF21-resistant state. FGF21 treatment significantly down-regulated FGF21 receptor components and activated ERK phosphorylation. FGF21 administration also markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic molecule synthesis. Furthermore, FGF21 improved renal lipid metabolism and oxidative stress injury. In cultured renal cells, FGF21 was mainly expressed in mesangial cells, and knockdown of FGF21 expression by stealth small interfering RNA further aggravated high-glucose-induced profibrotic cytokine synthesis in mesangial cells. Our results suggest that FGF21 improves insulin resistance and protects against renal injury through both improvement of systemic metabolic alterations and antifibrotic effects in type 2 diabetic nephropathy. Targeting FGF21 could therefore provide a potential candidate approach for a therapeutic strategy in type 2 diabetic nephropathy.

scholarly journals Serum Fibroblast Growth Factor 21 Levels Are Correlated with the Severity of Diabetic Retinopathy

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Yuan Lin ◽  
Ye-cheng Xiao ◽  
Hong Zhu ◽  
Qing-yan Xu ◽  
Lei Qi ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Insulin ◽  
Conditional Logistic Regression ◽  
Fasting Blood Glucose ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Model Assessment ◽  
Fibroblast Growth

The aim of the study was to assess serum fibroblast growth factor 21 (FGF21) concentrations in Chinese type 2 diabetic patients with and without retinopathy and to assess the association between FGF21 and the severity of retinopathy. 117 diabetic patients were compared with 68 healthy controls. Fasting blood glucose, serum total cholesterol, serum triglycerides, serum insulin, and serum FGF21 levels were estimated. FGF21 concentrations in the patients were significantly higher than those in control. In the patient group there was a significant positive correlation between FGF21, insulin level, and homeostasis model assessment index. Serum FGF21 concentrations in patients with proliferative diabetic retinopathy or nonproliferative diabetic retinopathy were significantly higher than those in patients without diabetic retinopathy. When the presence of diabetes was defined as the final variable in the conditional logistic regression model with the FGF21 concentration as the continuous variable, FGF21 was significantly involved in the model. This study shows that the increase in serum concentration of FGF21 was associated with the severity of diabetic retinopathy and suggests that FGF21 may play a role in the pathogenesis of diabetic retinopathy and its degree.

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

2020 ◽  
Author(s):  
Wangshu Liu ◽  
Tianli Xu ◽  
Mengjie Tang ◽  
Xue-Qin Wang ◽  
Jianbin Su ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Fibroblast Growth Factor 19 ◽  
Type 2 Diabetic

Abstract BackgroundWe aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients.MethodsSerum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated.ResultsT2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP (p for trend < 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level (p < 0.05). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant (p < 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) (p < 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p < 0.01).ConclusionsSerum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.

Sign in / Sign up

Export Citation Format

Share Document